Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jacqueline H M, van Kuijk"'
Autor:
André M. M. Miltenburg, Marita Prohn, Renger G. Tiessen, Jacqueline H. M. van Kuijk, Martin de Kort, Rob J. W. Berg
Publikováno v:
British Journal of Clinical Pharmacology. 75:1221-1230
Aim Conjugation to antithrombin III ATIII-binding pentasaccharides has been proposed as a novel method to extend the half-life of therapeutic proteins. We aim to validate this technological concept in man by performing a first-in-human study using Ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::703d7d259ebd386b1f009a31a8f4a9c6
https://doi.org/10.1111/j.1365-2125.2012.04460.x
https://doi.org/10.1111/j.1365-2125.2012.04460.x
Autor:
Jacqueline H. M. van Kuijk, Pierre A. M. Peeters, Pieter-Jan de Kam, T. Thomsen, Marita Prohn
Publikováno v:
Clinical Drug Investigation. 30:599-611
Sugammadex reverses the effects of rocuronium- and vecuronium-induced neuromuscular blockade, which are achieved by encapsulation. It is known that some non-antiarrhythmic drugs have the potential to delay cardiac repolarization and it is therefore r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f41cd2f128e545d5c4eeddb051a16a15
https://doi.org/10.2165/11537210-000000000-00000
https://doi.org/10.2165/11537210-000000000-00000
Autor:
Benoit Plaud, Olli A. Meretoja, Yvonne Hermens, Rainer Hofmockel, Julien Raft, Peter A. Stoddart, Jacqueline H. M. van Kuijk, Rajinder K. Mirakhur
Publikováno v:
Anesthesiology. 110:284-294
Background: Sugammadex reverses neuromuscular blockade by chemical encapsulation of rocuronium. This phase IIIA study explored efficacy and safety of sugammadex in infants (28 days to 23 months), children (2‐11 yr), adolescents (12‐17 yr), and ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::292d802accd8deaec17b62b527b626ae
https://doi.org/10.1097/aln.0b013e318194caaa
https://doi.org/10.1097/aln.0b013e318194caaa
Autor:
Jacqueline H. M. van Kuijk, Robert I McLachlan, Aleksander Giwercman, Ann J. Conway, Gerrit Voortman, Pierre Bouloux, Gordon H.W. Baker, Leo Turner, Annemarie Syska, David J. Handelsman, Henry G. Burger, Eberhard Nieschlag, Robert Ochsenkuehn, Niels E. Skakkebæk, Frederick C. W. Wu
Publikováno v:
Journal of Andrology. 24:604-611
A multicenter, open-label, randomized efficacy and safety study was performed with combined human chorionic gonadotropin (hCG) and recombinant follicle-stimulating hormone (recFSH) (Puregon(R)) treatment to induce spermatogenesis in hypogonadotropic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f32adf35189604859225bfa572af496
https://doi.org/10.1002/j.1939-4640.2003.tb02712.x
https://doi.org/10.1002/j.1939-4640.2003.tb02712.x
Publikováno v:
International journal of clinical pharmacology and therapeutics. 50(8)
Objective Sugammadex is a novel γ-cyclodextrin and the first selective relaxant binding agent to be developed for the reversal of rocuronium and vecuroniuminduced neuromuscular blockade. According to International Conference on Harmonization (ICH) E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6bd1999a4c7c77501d768106e058872
https://pubmed.ncbi.nlm.nih.gov/22735462
https://pubmed.ncbi.nlm.nih.gov/22735462
Autor:
André M M, Miltenburg, Marita, Prohn, Jacqueline H M, van Kuijk, Renger G, Tiessen, Martin, de Kort, Rob J W, Berg
Publikováno v:
British journal of clinical pharmacology. 75(5)
Conjugation to antithrombin III ATIII-binding pentasaccharides has been proposed as a novel method to extend the half-life of therapeutic proteins. We aim to validate this technological concept in man by performing a first-in-human study using CarboC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cdf0da5f0e1bc009f9a00aadfc1d65db
https://pubmed.ncbi.nlm.nih.gov/22978318
https://pubmed.ncbi.nlm.nih.gov/22978318